tavapadon

Indications

• experimental treatment of Parkinson's disease (phase 3 trial)

Dosage

• 5 mg to 15 mg PO QD

Adverse effects

• decrease in supine blood pressure
• weight loss
• > 5%
  • nausea (36 vs 11)*
  • dyskinesia (25 vs4)
  • dizziness (19 vs5)
  • headache (17 vs 7)
  • orthostatic hypotension (15 vs 3)
  • visual hallucination (14 vs 3)*

* tavapadon vs placebo

Mechanism of action

• selective partial D1/D5 dopamine receptor agonist
  • agonist for dopamine D1 receptors & dopamine D5 receptors

More general terms

• neurologic agent

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=86764100